About UsIDS is headquartered in the UK, and has subsidiaries in the USA, Germany, France, Denmark, Finland and Belgium, offering next day delivery in all major territories. The markets of Spain, Italy, Australia, Japan and elsewhere are serviced by a network of highly qualified and experienced distributors. You will find full contact details of all of these outlets on this website.

The company enjoys a dominant position in the provision of immunoassay kits for the determination of Vitamin D (for the more technical, both 25 Hydroxy- and 1,25 Dihydroxy- Vitamin D). We are determined to remain at the forefront of Vitamin D testing globally, and the appearance of fully automated Vitamin D on the IDS-iSYS underlines this determination.

Our track record of delivering innovative new products, by de novo or collaborative programmes with academia, or the judicious acquisition of complementary products and/or companies, has given IDS the broadest range of bone and skeletal biomarker kits available anywhere in the world.

Our entry into the automated analyser market heralds a new phase of growth for IDS. The IDS-iSYS is a push-button, walk away instrument that is multi-competent – a fully-automated immunoanalyser that can simultaneously run biochemistry and haemostasis tests from the same patient primary sample tube.

IDS meet the needs of its pharmaceutical and clinical customers by providing a range of Research Use Only kits for researchers in drug development and pre-clinical studies, and in offering fully-optimised and validated human kits for ensuing clinical studies, and ultimately for use by the Clinical Chemist for routine IVD purposes.

With fully-automated instrumentation, IDS will compete more effectively for the larger accounts in reference laboratories and Clinical Research Organisations, whilst also easing the pressure of growing volumes of testing being experienced by small to mid sized laboratories.

The increase in the aging population throughout the world has resulted in a higher incidence of conditions such as osteoporosis, rheumatoid and osteo- arthritis, renal and cardiovascular disease. The spiralling socio-economic costs of fractures and other age-related morbidities are driving the need for better tools to monitor health and diagnose disease onset much earlier, and IDS intends to play a full part in this.